Methazolamide Attenuates the Development of Diabetic Cardiomyopathy by Promoting beta-Catenin Degradation in Type 1 Diabetic Mice

Methazolamide (MTZ), a carbonic anhydrase inhibitor, has been shown to inhibit cardiomyocyte hypertrophy and exert a hypoglycemic effect in patients with type 2 diabetes and diabetic db/db mice. However, whether MTZ has a cardioprotective effect in the setting of diabetic cardiomyopathy is not clear. We investigated the effects of MTZ in a mouse model of streptozotocin-induced type 1 diabetes mellitus (T1DM). Diabetic mice received MTZ by intragastric gavage (10, 25, or 50 mg/kg, daily for 16 weeks). In the diabetic group, MTZ significantly reduced both random and fasting blood glucose levels and improved glucose tolerance in a dose-dependent manner. MTZ ameliorated T1DM-induced changes in cardiac morphology and dysfunction. Mechanistic analysis revealed that MTZ blunted T1DM-induced enhanced expression of beta-catenin. Similar results were observed in neonatal rat cardiomyocytes (NRCMs) and adult mouse cardiomyocytes treated with high glucose or Wnt3a (a beta-catenin activator). There was no significant change in beta-catenin mRNA levels in cardiac tissues or NRCMs. MTZ-mediated beta-catenin downregulation was recovered by MG132, a proteasome inhibitor. Immunoprecipitation and immunofluorescence analyses showed augmentation of AXIN1-beta-catenin interaction by MTZ in T1DM hearts and in NRCMs treated with Wnt3a; thus, MTZ may potentiate AXIN1-beta-catenin linkage to increase beta-catenin degradation. Overall, MTZ may alleviate cardiac hypertrophy by mediating AXIN1-beta-catenin interaction to promote degradation and inhibition of beta-catenin activity. These findings may help inform novel therapeutic strategy to prevent heart failure in patients with diabetes.